Papillary thyroid carcinoma is a risk factor for severe osteoporosis
| Autor: | Toshitsugu Sugimoto, Mika Yamauchi, Masakazu Notsu, Miwa Morita, Kiyoko Nawata |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Urinary system Osteoporosis 030209 endocrinology & metabolism Logistic regression Gastroenterology 03 medical and health sciences 0302 clinical medicine Endocrinology Bone Density Risk Factors Internal medicine medicine Prevalence Humans Orthopedics and Sports Medicine Thyroid Neoplasms Risk factor Thyroid cancer business.industry General Medicine Odds ratio Middle Aged medicine.disease Confidence interval Thyroid Cancer Papillary Case-Control Studies Female 030101 anatomy & morphology Bone Remodeling business Body mass index Biomarkers |
| Zdroj: | Journal of bone and mineral metabolism. 38(2) |
| ISSN: | 1435-5604 |
| Popis: | Thyroid-stimulating hormone (TSH)-suppressive therapy is recommended after surgical treatment in high-risk papillary thyroid carcinoma (PTC) patients. TSH-suppressive therapy is a known risk factor for osteoporosis and fractures. However, whether patients with PTC themselves are at a higher risk of osteoporosis than healthy individuals remains unclear. This study aimed to clarify whether PTC is a risk factor for osteoporosis. Serum and urinary biochemical parameters, bone mineral density (BMD), and presence of vertebral fractures (VFs) and non-VFs were evaluated in 35 PTC patients and 35 age- and sex-matched healthy individuals. We compared the parameters between PTC and control subjects and performed multiple logistic regression analyses after adjustments for variables. Patients with PTC had higher body mass index (BMI) and hemoglobin (Hb)A1c, as well as lower eGFR and intact PTH than controls (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink